Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Group 1 - Gilead Sciences (GILD) has gained approximately 16.5% year-to-date, outperforming the average gain of 5.6% in the Medical sector [4] - Gilead Sciences holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for GILD's full-year earnings has increased by 7.7% over the past quarter, reflecting improved analyst sentiment [3] Group 2 - Gilead Sciences is part of the Medical - Biomedical and Genetics industry, which includes 510 stocks and is currently ranked 67 in the Zacks Industry Rank [5] - Stocks in the Medical - Biomedical and Genetics industry have gained about 5.8% year-to-date, indicating GILD's strong performance relative to its peers [5] - Another outperforming stock in the Medical sector is Natera (NTRA), which has increased by 9% year-to-date and also holds a Zacks Rank of 2 (Buy) [4][5]